Lonza Expands U.S. Operations with Acquisition of Five CDMO Sites from Merck KGaA
- Lonza will acquire five U.S. manufacturing sites from Merck KGaA, increasing its U.S. presence from four to nine sites.
- The acquisition adds approximately 1,100 employees and is expected to generate about 250 million Swiss francs in sales by 2028.
Operational Impact
This acquisition significantly expands Lonza's U.S. manufacturing capabilities, particularly in bioconjugates and viral vectors, enhancing its ability to meet customer demand.
Source: Pharmaceutical Executive RSS
Lonza Acquires Merck KGaA's CDMO Business to Enhance US Manufacturing Capacity
- Merck KGaA has agreed to sell its CDMO business to Lonza for a mid-triple-digit million-euro amount, expected to close in mid-2027.
- The acquisition includes operations in California, Wisconsin, and Indiana, enhancing Lonza's capabilities and manufacturing capacity in the US.
Operational Impact
This acquisition will expand Lonza's US manufacturing capacity, allowing it to better support customers in the biopharmaceutical sector.
Source: BioProcess International RSS